A Healthy, Happier Life Takes Committment On Your Part

Treatment for Rosacea Just Got Approved by the FDA

Rosacea sufferers can attest to the fact that there are many products that promise to control the symptoms of their condition, however, a lot of these fail to deliver outstanding results. The maker of the popular beauty chemical Botox and breast implants – Allergan – is now saying that they could have the solution that rosacea patients have been waiting for. They already received the green light from FDA to legally distribute Rhofade, a topical cream for the skin redness associated with the rosacea condition. Rhofade is a 1% oxymetazoline hydrochloride cream.

How does the cream work? For people with rosacea, the blood vessels in the face have the tendency to be overactive, causing them to flush faster compared to other people. Eventually, the redness will become worse where this will become a permanent condition on the face. When people use Rhofade, they will experience tightening of the blood vessels, which, in turn, helps lessen the redness on the face.

Allergan was able to get the approval of FDA after having elicited positive results in two clinical trials. Those who used the cream reported reduced redness in a 12-hour period. Their condition improved further as they continued to use the product within the trial period of 29 days. The results are considered a breakthrough for rosacea patients since this now presents a possible permanent solution although it’s still too early to tell. Rosacea is considered a progressive condition; it gets worse as the patient gets older. Until the creation of Rhofade, patients relied on solutions that only treated the other symptoms associated to rosacea but not the redness.

Although it already received the go signal of the FDA, rosacea sufferers will have to wait a little while longer before they can try this product. Allergan says that Rhofade will be officially available, albeit by prescription beginning May 2017 in the United States.

Leave a Comment:

All fields with “*” are required

Leave a Comment:

All fields with “*” are required